Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Consensus Recommendation of “Buy” by Brokerages

Definium Therapeutics, Inc. (NASDAQ:DFTX) has earned an average recommendation of “Buy” from the eighteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $57.00.

A number of brokerages have recently issued reports on DFTX. Wells Fargo & Company initiated coverage on Definium Therapeutics in a report on Monday, July 27th. They issued an “overweight” rating and a $68.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Wall Street Zen cut Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, JonesTrading increased their price objective on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported positive topline results from the Phase 3 Voyage study. DT120 produced a 5.4-point improvement on the Hamilton Anxiety Rating Scale versus placebo, supporting the drug’s efficacy in GAD and marking the second positive Phase 3 study for the program. Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study
• Positive Sentiment: The results generated substantial investor interest because DT120 now has positive late-stage data in two potential indications. Investors are also watching for a further catalyst expected in September 2026. This LSD-Based Drug Just Scored Again
• Positive Sentiment: Needham raised its price target on DFTX from $50 to $66 and maintained a Buy rating, implying considerable additional upside based on the stock level cited in the report. Benzinga analyst update
• Neutral Sentiment: Trading in DFTX was temporarily halted for news pending before the clinical announcement, underscoring the market-moving nature of the trial results. Definium says LSD-based pill reduces anxiety in late-stage study
• Negative Sentiment: HC Wainwright lowered its earnings forecasts across 2026–2030, including FY2026 EPS to $(3.05) from $(2.10) and FY2027 EPS to $(1.71) from $(1.22). The revisions highlight continued losses and the time required for DT120 to generate commercial earnings. Definium Therapeutics analyst estimates

Definium Therapeutics Stock Performance

NASDAQ DFTX opened at $42.79 on Friday. Definium Therapeutics has a twelve month low of $8.70 and a twelve month high of $49.70. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock has a market cap of $4.27 billion, a P/E ratio of -12.48 and a beta of 2.23. The company’s 50-day simple moving average is $39.06 and its 200 day simple moving average is $26.52.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, research analysts forecast that Definium Therapeutics will post -2.81 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the transaction, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This trade represents a 2.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the sale, the chief financial officer directly owned 209,487 shares in the company, valued at $9,433,199.61. This represents a 1.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 48,096 shares of company stock worth $2,165,763 in the last quarter. 2.40% of the stock is owned by company insiders.

Institutional Trading of Definium Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Commodore Capital LP grew its holdings in Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after acquiring an additional 475,000 shares during the last quarter. Orbimed Advisors LLC bought a new position in shares of Definium Therapeutics in the third quarter worth about $4,337,000. Two Sigma Investments LP lifted its position in shares of Definium Therapeutics by 424.9% during the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after purchasing an additional 239,965 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Definium Therapeutics by 11.0% during the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after purchasing an additional 198,878 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Definium Therapeutics by 62.6% during the third quarter. Millennium Management LLC now owns 298,205 shares of the company’s stock worth $3,516,000 after purchasing an additional 114,805 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.